ImExHS Limited AI Stock Analysis
Want to see AU:IME full AI Analyst Report?
ImExHS Limited (IME) AI Stock Analysis
ImExHS Limited
(ASX:IME)
The score is primarily held back by weak profitability (ongoing losses, negative margins, and a notable gross margin decline) despite improving revenue growth and a turnaround to positive operating/free cash flow. Technicals are mildly supportive in the short term (above key short/intermediate moving averages), but the long-term trend and MACD remain soft. Valuation is a significant headwind given the very high P/E and lack of dividend yield support.
ImExHS Limited (IME) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 16.86M
- Dividend Yield
- ―
- Average Volume (3M)
- 16.72K
- Price to Earnings (P/E)
- 88.6
- Beta (1Y)
- 0.46
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Australia
- Employees
- 290
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
ImExHS Limited Business Overview & Revenue Model
Company Description
ImExHS Limited delivers cloud-powered medical imaging technologies to customers worldwide, including those in Australia. The firm specializes in the development and sale of modular imaging software systems, which encompass comprehensive information m...
ImExHS Limited Financial Statement Overview
Summary
Revenue growth accelerated to 10.0% in 2025, and operating/free cash flow turned positive (OCF 0.56M; FCF 0.24M), which improves resilience. However, profitability remains weak with persistent net losses (2025 net margin -9.9%), negative operating margin (-2.4%), and a sharp gross margin decline (28.7% vs 41.5% in 2024). The balance sheet is low leverage (debt-to-equity 0.04), but returns are still negative (ROE -18.2%).
Income Statement
44NeutralBalance Sheet
74PositiveCash Flow
52Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 31.26M | 28.97M | 26.57M | 19.67M | 17.12M | 13.37M |
| Gross Profit | 10.13M | 8.31M | 11.03M | 3.50M | 3.52M | 5.22M |
| EBITDA | 2.53M | 1.52M | 45.18K | -1.26M | -744.67K | -3.01M |
| Net Income | 188.61K | -2.88M | -2.63M | -4.19M | -3.04M | -4.70M |
Balance Sheet | ||||||
| Total Assets | 26.57M | 23.73M | 21.81M | 22.65M | 20.99M | 25.01M |
| Cash, Cash Equivalents and Short-Term Investments | 1.99M | 3.30M | 2.07M | 2.36M | 1.91M | 4.19M |
| Total Debt | 455.34K | 566.32K | 1.19M | 1.29M | 1.12M | 2.40M |
| Total Liabilities | 9.35M | 7.86M | 7.33M | 6.67M | 5.09M | 8.36M |
| Stockholders Equity | 17.22M | 15.87M | 14.47M | 15.98M | 15.90M | 16.65M |
Cash Flow | ||||||
| Free Cash Flow | 1.28M | 244.16K | -1.69M | 414.59K | -4.23M | -5.53M |
| Operating Cash Flow | 1.49M | 564.71K | -634.68K | 2.61M | -2.20M | -2.97M |
| Investing Cash Flow | -1.18M | -1.19M | -765.91K | -2.13M | -2.22M | -3.39M |
| Financing Cash Flow | -1.10M | 1.68M | 1.18M | -98.61K | 2.25M | -161.78K |
ImExHS Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IME, the sentiment is Negative. The current price of 0.31 is below the 20-day moving average (MA) of 0.33, below the 50-day MA of 0.32, and below the 200-day MA of 0.35, indicating a bearish trend. The MACD of 0.00 indicates Positive momentum. The RSI at 33.78 is Neutral, neither overbought nor oversold. The STOCH value of 21.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IME.
ImExHS Limited Peers Comparison
Overall Rating
AU:ALC69Neutral
AU:IME53Neutral
AU:ONE48Neutral
AU:BMT45Neutral
AU:M7T43Neutral
AU:PCK38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 69Neutral | AUD 168.73M | 71.18 | 2.53% | ― | 26.61% | 38.21% | |
| 53Neutral | AUD 17.95M | 88.57 | 1.14% | ― | ― | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | AUD 104.90M | -6.42 | -203.69% | ― | -1.53% | 28.29% | |
| 45Neutral | AUD 20.08M | -1.08 | -58.13% | ― | 2.08% | -195.31% | |
| 43Neutral | AUD 61.10M | -6.84 | -24.29% | ― | -17.35% | -47.29% | |
| 38Underperform | AUD 14.02M | -1.54 | -1688.04% | ― | 11.45% | 0.69% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:IME | ImExHS Limited | 0.31 | 0.04 | 14.81% | |
| AU:ONE | Oneview Healthcare PLC Chess Depository Interests repr 1 | 0.13 | -0.16 | -56.90% | |
| AU:M7T | Mach7 Technologies Ltd. | 0.26 | -0.09 | -25.71% | |
| AU:BMT | Beamtree Holdings Ltd | 0.07 | -0.13 | -66.00% | |
| AU:ALC | Alcidion Group Limited | 1.20 | 0.20 | 19.50% | |
| AU:PCK | PainChek Ltd | 0.07 | -0.33 | -83.21% |
ImExHS Limited Corporate Events
IMEXHS lifts revenue as AI platform scales but software bookings lag
IMEXHS reported Q3 FY26 revenue of $8.9 million, up 23 per cent year on year, with year-to-date revenue rising 19 per cent to $24.8 million and underlying EBITDA doubling to $1.9 million. Cash increased to $2.5 million and debt fell to $0.17 million,...
ImExHS trims capital structure as over 260,000 options lapse
ImExHS Limited has notified the market of the cessation of several tranches of options, following a review of its issued capital. The affected securities include options expiring in 2034, 2035 and 2036, all with nil exercise price, that have now laps...
ImExHS Delivers Strong 1H FY26 Growth as AI Radiology Platform Gains Traction
ImExHS reported a solid first half of FY26, with revenue rising 17% year-on-year to $16 million and underlying EBITDA improving to $1.3 million, while annualised recurring revenue climbed 12% to $36.8 million. Debt was reduced to $0.25 million, thoug...
ImExHS Posts Half-Year Profit Turnaround and Strengthens Asset Base
ImExHS Limited reported a strong improvement in its financial performance for the half-year ended 30 June 2026, with revenues from ordinary activities rising 16.8% to $15.95 million. The company achieved a turnaround to a post-tax profit of $66,200,...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 15, 2026
